An optimal predictive model for OS was obtained with the tumor subtype (triple-negative) and polymorphisms within the gene encoding the target of bevacizumab itself: VEGFA (rs833061 C/C), as well as within the genes encoding its receptors (VEGFR1; rs9582036 C/A or C/C and VEGFR2; rs1870377 T/T). Here, FLT1 is linked to neoplasm.